

OUR PIPELINE

LAST UPDATED: FEBRUARY 22, 2024

We are building a pipeline of in vivo and ex vivo therapies, as well as continuing to develop innovative modular platform capabilities.

IN VIVO PROGRAMS

IN VIVO CRISPR **is** the therapy
GENETIC DISEASES

PROGRAM	APPROACH	RESEARCH AND PRECLINICAL	EARLY-STAGE CLINICAL	LATE-STAGE CLINICAL	PARTNERS
NTLA-2001 Transthyretin Amyloidosis	Knockout	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div>LEAD</div> <div>Intellia THERAPEUTICS</div> <div>REGENERON</div>
NTLA-2002 Hereditary Angioedema	Knockout	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div>Intellia THERAPEUTICS</div>
NTLA-3001 AATD-Lung Disease	Insertion	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div>Intellia THERAPEUTICS</div>
Hemophilia A / B**	Insertion	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div>LEAD</div> <div>Intellia THERAPEUTICS</div> <div>REGENERON</div>
Research Programs	Knockout, insertion or repair	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div>Intellia THERAPEUTICS</div>
Research Programs	Tissues outside the liver	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div>Intellia THERAPEUTICS*</div> <div>ReCode REGENERON SPARINGVISION</div>

EX VIVO PROGRAMS

EX VIVO CRISPR **creates** the therapy
IMMUNO-ONCOLOGY / AUTOIMMUNE DISEASE

PROGRAM	APPROACH	RESEARCH AND PRECLINICAL	EARLY-STAGE CLINICAL	LATE-STAGE CLINICAL	PARTNERS
Research Programs	Allogeneic and other	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div>Intellia THERAPEUTICS*</div> <div>kyverna</div> <div>AVENCELL</div> <div>ONK THERAPEUTICS</div>

AATD: Alpha-1 Antitrypsin Deficiency

Lead refers to lead development and commercial party.

* Intellia is advancing both wholly owned and partnered programs.
** Hemophilia A program is in the research stage.